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Background: This article outlines procedures for the feedback of individual research data to participants. This
feedback framework was developed in the context of a personalized medicine research project in Canada.
Researchers in this domain have an ethical obligation to return individual research results and/or material incidental
findings that are clinically significant, valid and actionable to participants. Communication of individual research
data must proceed in an ethical and efficient manner. Feedback involves three procedural steps: assessing the health
relevance of a finding, re-identifying the affected participant, and communicating the finding. Re-identification requires
researchers to break the code in place to protect participant identities. Coding systems replace personal identifiers with
a numerical code. Double coding systems provide added privacy protection by separating research data from personal
identifying data with a third “linkage” database. A trusted and independent intermediary, the “keyholder”, controls
access to this linkage database.
Discussion: Procedural guidelines for the return of individual research results and incidental findings are lacking. This
article outlines a procedural framework for the three steps of feedback: assessment, re-identification, and communication.
This framework clarifies the roles of the researcher, Research Ethics Board, and keyholder in the process. The framework
also addresses challenges posed by coding systems. Breaking the code involves privacy risks and should only be carried
out in clearly defined circumstances. Where a double coding system is used, the keyholder plays an important role in
balancing the benefits of individual feedback with the privacy risks of re-identification.
Summary: Feedback policies should explicitly outline procedures for the assessment of findings, and the re-identification
and contact of participants. The responsibilities of researchers, the Research Ethics Board, and the keyholder must be
clearly defined. We provide general guidelines for keyholders involved in feedback. We also recommend that Research
Ethics Boards should not be directly involved in the assessment of individual findings. Hospitals should instead establish
formal, interdisciplinary clinical advisory committees to help researchers determine whether or not an uncertain finding
should be returned.
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A feedback policy (also “communication” or “disclosure”
policy) addresses a range of communications with partici-
pants such as re-contact to gather additional information
or carry out new tests, dissemination of general study
results, and the return of individual research data. De-
bate continues over what individual genetic data, if any,
researchers should offer to participants [1]. Individual
genetic data includes individual research results and in-
cidental findings. Individual research results (“IRRs”)
are results of the research project that concern the
health status of individual participants. Incidental find-
ings (“IFs”) also concern an individual participant’s
health, but are findings encountered outside the objec-
tives of the research project. Pressure to disclose these
two forms of individual research data has mounted with
the advent of new genetic sequencing technologies,
which reveal swaths of health information, and an in-
creasing emphasis on translational research. Susan Wolf
[2] characterizes the question of feedback as “funda-
mentally a problem of translational science – a question
of when information about an individual that is gener-
ated in research should be communicated for clinical at-
tention”. A feedback policy should not only describe
what kinds of individual research data will be returned
to participants; it should also describe the procedures
through which the data will be returned. But what form
should feedback procedures take?
This article outlines an implementation framework for
the return of individual research data (IRRs and IFs) to
participants. It is based on our experience in developing
a feedback policy for the Liver Disease Project (LDP) at
the Research Institute of the McGill University Health
Centre, the McGill University Health Centre and McGill
University in Montréal, Québec. The LDP is a personal-
ized medicine project mainly funded through a stra-
tegical grant awarded to the Research Institute by the
Fonds de recherche du Québec - Santé. Our framework is
suited to similar personalized research projects based in
Canada, though it may offer a useful example to any re-
search project communicating individual research data
and using a coding system to protect participant privacy.
This article does not aim to resolve the debate over what
information, if any, should be returned to research par-
ticipants. Feedback practices remain diverse across juris-
dictions and research contexts and disagreement persists
over whether or not researchers have an obligation to
return IRRs and IFs. Instead, we focus on how informa-
tion should be communicated to consenting partici-
pants once the decision to return IRRs or IFs has been
made. The feedback process involves three central
steps: assessing an IRR or IF, breaking the code to re-
identify the participant, and communicating the find-
ing to the participant.This article is divided into a Background, Discussion,
and Summary. The rest of this Background comprises of
3 subsections. The first subsection outlines the emerging
ethical duty of researchers to return IRRs and IFs to par-
ticipants. The second describes coding systems used to
protect participant privacy. The third describes the LDP,
along with its associated biobank, the Liver Disease
Biobank, and details the Feedback Policy we developed
for this project. In our Discussion, we identify proced-
ural issues that may arise during the feedback of individual
research data. First, “coding” of samples and data –
delinking of personal identifiers from sensitive health
information to protect privacy – complicates future com-
munication and feedback to participants. Second, the roles
of the principal investigator, the keyholder and the Re-
search Ethics Board (REB) (the Canadian equivalent of an
Institutional Review Board) in the feedback process are
not adequately defined in the literature. We recommend
that the REB’s role should be limited to the review and ap-
proval of the plan and procedures for the return of IRRs
and IFs. Responsibility for assessing IRRs and IFs should
remain with the principal investigator of the project. In
uncertain cases, researchers should approach their clinical
colleagues. Ideally, research institutions should establish
a formal, interdisciplinary clinical advisory committee
to assist researchers in this assessment. If a double cod-
ing system is employed, participants will need to be re-
identified by a keyholder before they can be contacted.
Re-identification involves privacy risks, and should only
be carried out by the keyholder in clearly defined cir-
cumstances. We provide guidelines outlining the role
and responsibilities of this keyholder. Procedural issues
are serious obstacles to the ethical and efficient return
of IRRs and IFs, yet they have received little attention in
the literature and guidelines [3]. Our recommendations
aim to provide direction for the return of IRRs and IFs,
and to promote discussion about the roles of the actors
involved.The researcher’s duty to return individual research results
and incidental findings to participants
There is growing consensus in Canada that researchers
have an ethical obligation to return certain health infor-
mation to participants. This obligation is founded on the
ethical principles of beneficence, reciprocity, and respect
for persons. First, certain research findings could directly
benefit individual participants. Second, communicating
findings to participants gives them something in return
for their contribution. Reciprocity reflects the idea “that
individuals who voluntarily agree to contribute to research
be provided some kind of access to the knowledge gained
from such research” [4]. Finally, acting in the individual
participant’s interest is a concrete expression of respect:
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a means to knowledge generation.
The literature distinguishes between four forms of
participant feedback – general research results, baseline
assessment results, IFs, and IRRs. These divisions may be
far from clear in practice. The Public Partnership Project
in Genomics and Society (P3G), an international consor-
tium of population biobanks, offers the following defini-
tions in a recent policy statement:
Baseline Assessment: includes measurements such as
blood pressure, lung function, bone density, height,
weight, fat, and others (taken at baseline or at any
subsequent assessment).
General Results: aggregate results drawn from the analysis
of data and samples of a group of research participants.
Incidental Findings: unforeseen findings concerning a
research participant that have potential health or
reproductive importance. They are discovered during
the course of research but are outside its objectives.
Individual Research Results: results discovered during the
course of research, which concern an individual participant,
and have potential health or reproductive impact [5].
We focus on feedback procedures for IFs and IRRs
from a biobank with a coding system. The return of in-
dividual research data raises distinct ethical and policy
issues from the return of general results, and is more
controversial than the return of baseline assessment re-
sults. To date, the debate has focused on determining
what findings should be returned, either by defining gen-
eral criteria, or by developing consensus-generating pro-
cedures in a given research community. Disagreement
persists over what general substantive criteria must be
met to trigger the obligation to return IFs or IRRs. This
article does not aim to revisit this debate. It is, however,
generally agreed upon in Canada that: “findings that are
analytically valid, reveal an established and substantial
risk of a serious health condition, and that are clinically
actionable should generally be offered to consenting con-
tributors” [6]. A list of major US and Canadian guidelines
can be found in Table 1.
The extent of feedback of IRRs or IFs to participants
will depend on the research context. The research proto-
col determines what information is collected and how it is
analyzed, and therefore determines the likelihood that the
research will generate findings of clinical relevance to par-
ticipants. Other aspects of the research context determin-
ing the scope of the researcher’s duty to return individual
research data are the vulnerability and dependence of the
study population; whether a clinical relationship already
exists between researcher and participant; the intensity
and duration of their interactions; and the availability of
adequate funding, personnel, and technology. (For acomplete list, see [3], Table One; [13]). Extensive vari-
ation exists between jurisdictions, research projects, and
the types of information they will return to participants.
Often, researchers opt to return only limited subsets of
IRRs or IFs. They may decide to return only IRRs, only
IFs, both or neither. In some cases, it may be difficult to
distinguish these two categories of research data. The
framework we present is relevant to researchers plan-
ning to return any type of individual research data, and
is particularly suited to the personalized medicine re-
search context, described below.
Quite apart from the debate over what individual feed-
back to offer participants, are procedural questions of
how to assess individual research data, re-identify partic-
ipants, and communicate sensitive health information to
them. These questions are largely overlooked in the litera-
ture. This oversight is understandable for several reasons.
Uncertainty about what information should be returned
overshadows the question of how it will be returned. The
heterogeneity of research context and biobanks inhibits
the generation of policy guidance for return procedures
[3]. Uneven treatment of substance and procedure is evi-
dent in existing guidelines. For example, major Canadian
research funding bodies stipulate that IFs should be dis-
closed if “interpreted as having significant welfare implica-
tions for the participant” [14]; the definition given for
“welfare” is extremely broad. However, where such find-
ings are likely, researchers are simply instructed to “de-
velop a plan indicating how they will disclose such
findings to participants” [14]. No guidance is provided as
to what such a plan might need to include.
The problem of ambiguity and inconsistency identified
in policies at the national level becomes acute when re-
search relies on biobanks, especially where the biobank is
intended to serve researchers residing in different jurisdic-
tions, each having its own policy on the matter. The prob-
lem is further compounded by limited awareness on the
part of researchers and funding organizations of the costs
of designing and implementing procedures for the feedback
of individual health data. The factors determining these
costs must be contemplated by “researchers in planning
their budgets and funding agencies in determining the ap-
propriate level and duration of funding” [15]. In addition to
costs, risks must also be considered. Offering personal
feedback of health information may promote the thera-
peutic misconception and induce participation. The return
of uncertain information may also upset participants, or
lead them to undergo unnecessary and potentially harmful
follow-up testing.
The relationship between privacy protection and
feedback of individual data
A central complication for the feedback of IFs or IRRs is
the coding of biomaterials and data. Many research
Table 1 Research guidelines: return of IRRs and IFs to participants
Network of Applied Genetic Medicine, Statement
of Principles on the Return of Research Results
and Incidental Findings (2013) (Summary) [7].
Principle 2: Individual Results And Incidental Findings That Should Be Offered
Individual results and incidental findings should be offered to participants when:
1) they are material, i.e. when the following conditions are met:
1.1) they meet generally accepted criteria of scientific and clinical validity (criteria which
are widely recognised by the medical community);
1.2) they have clinical utility for the participant, i.e.:
- the benefits associated with the communication of the results outweigh the risks;
- prevention or treatment is available; and
- individual, familial and social factors were considered;
2) exceptions and additional considerations related to the research context have been weighed;
3) REB approval has been obtained;
4) the participant has consented to the return of results; and
5) the research result has been confirmed.
Principle 3: Individual Results And Incidental Findings That May Be Offered
Individual results and incidental findings that are not compliant with the criteria set out in
Principle 2 may be offered to participants (i.e. at the researcher’s discretion) when:
1) they meet generally accepted criteria of scientific and clinical validity;
2) the benefits of return surpasses the risks;
3) REB approval has been obtained;
4) the participant consented to the return; and
5) the research result has been confirmed.
Principle 4: Individual Results And Incidental Findings That Have Implications For Family
Members
It is possible that individual results and incidental findings have implications for the participant’s
BIOLOGICAL RELATIVES. Under certain circumstances, these results may be returned (i.e. at the
researcher’s discretion) to family members when:
1) they meet the generally accepted criteria of scientific and clinical validity;
2) the benefits of the return outweigh the risks;
3) REB approval has been obtained;
4) the research result has been confirmed;
5) the participant agrees to share the result with biological relatives; and
6) the biological relatives concerned agree to receive the results.
Public Population Project in Genomics and Society,
Population Studies: Return of Research Results and
Incidental Findings Policy Statement (2012) [5].
Return of IRRs and IFs to Participants: Conditions and Modalities
No Return of IRRs and IFs
There may be population studies where the policy is not to return individual results or findings,
and this was consented to by participants at recruitment. This remains a viable option where
appropriate. Researchers accessing the study population and their local Ethics Review Committee
should be made aware of this policy.
For population studies with a no-return policy or where participants did not consent at recruitment
to the return of findings but have, nonetheless, consented to recontact for updates and for further
questions or collection of samples, such a period can create an opportunity to explain and introduce
a return of results and IFs policy and accompanying procedures, if the population study so chooses
and with ethics approval. Indeed, upon recontact, participants could be provided with an option to
consent (or not) to receiving such results. Moving forward, population studies with a no return policy
could consider adding such an option to their consent process at recruitment.
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Table 1 Research guidelines: return of IRRs and IFs to participants (Continued)
Return of IRRs and IFs
Decision to return results: When consent to return results is present, one should consider whether
the finding poses a material risk. Findings are material if they have:
1) analytical validity;
2) clinical significance; and
3) actionability.
Researchers, in collaboration with their local Ethics Review Committee, should consider returning
IRRs and IFs to participants when they determine that the following criteria are met:
1) the participant has consented thereto in the initial consent form or at a later time;
2) the findings are analytically valid (ie, confirmed independently);
3) they reveal a significant risk of a serious health condition; and,
4) they are actionable.
Researchers, in collaboration with their local Ethics Review Committee, may consider
returning IRRs and IFs when the above criteria are not satisfied, but when the following
criteria are met:
1) the participant has consented thereto in the initial consent form or at a later time;
2) the findings are analytically valid (ie, confirmed independently);
3) they reveal an established risk of likely health importance to the participant; and
3) they have a likely therapeutic benefit.
The decision to return IRRs and IFs remains the responsibility of the researchers and the
local Ethics Review Committee. Resources should be available for this decision-making
process.
Communication of results. Contacting participants for the communication of material
findings remains the responsibility of the population study. The population study should
ensure the quality of the results, as well as the timeliness and appropriateness of the
information returned to a given participant (including considerations related to the
number of recontacts).
Procedures
Population studies should put in place policies and procedures that clarify and
circumscribe the obligations and procedures arising from their return of results policy.
These should be reflected in any material-transfer agreements and access policies for
researchers. These policies should include the length of duration of any return of results policy
and the degree of involvement of researchers. Attention should be paid to issues of feasibility and
reasonability. Procedures should be in place in the population study for the communication of such
results by a health professional.
National Bioethics Advisory Commission, Research
Involving Human Biological Materials: Ethical Issues
and Policy Guidance, Vol. 1. (1999) [8].
Return results only if
a. “the findings are scientifically valid and confirmed”
b. “the findings have significant implications for the subjects’ health concerns” and
c. “a course of action to ameliorate or treat these concerns is readily available.”
National Heart, Lung, and Blood Institute: Recommendation 1: IRRs “should be offered to study participants in a timely manner if they meet
all of the following criteria:
Fabsitz RR, McGuire A, Sharp RR, et al., Practical
Guidelines for Reporting Genetic Research Results
to Study Participants: Updated Guidelines from
an NHLBI Working Group (2010) [9].
a. The genetic finding has important health implications for the participant and the associated
risks are established and substantial.
b. The genetic finding is actionable, that is, there are established therapeutic or preventive
interventions or other available actions that have the potential to change the clinical course
of the disease.
c. The test is analytically valid and the disclosure plan complies with all applicable laws.
d. During the informed consent process or subsequently, the study participant has opted to
receive his/her individual genetic results.”
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Table 1 Research guidelines: return of IRRs and IFs to participants (Continued)
Recommendation 4 “Investigators may choose to return individual genetic results to study participants if
the criteria for an obligation to return results are not satisfied (see Recommendation 1) but all of the
following apply:
a. The investigator has concluded that the potential benefits of disclosure outweigh the risks
from the participant’s perspective.
b. The investigator’s Institutional Review Board (IRB) has approved the disclosure plan.
c. The test is analytically valid and the disclosure plan complies with all applicable laws.
d. During the informed consent process or subsequently, the study participant has opted to
receive his/her individual genetic results.”
Canadian College of Medical Geneticists and the
Canadian Association of Genetic Counsellors,
Joint Statement on the Process of Informed
Consent for Genetic Research (2008) [10].
7(vii). Disclosure of results
Research participants should be informed at the outset if the results from the study will be
disclosed and, if so, in what manner (e.g. individually to each participant or collectively as a study
group through publication or another means). […] As indicated in section 7(v) above, researchers
must take care to protect the privacy and confidentiality of individual participants in the course of
results disclosure. Researchers should ensure that participants do not have unrealistic expectations
with respect to disclosure of results. For example, a realistic estimate of the timeframe should be
communicated to the participant. Ideally, participants should have the option to decline to be
informed of study results at the time of enrollment or at any time during the study. It is
recommended that for all studies in which results will be disclosed, genetic counselling should
be a component of the informed consent process. The counselling provided should be
appropriate to the clinical impact of the study. It should be provided at a level of depth and by
staff with a level of training and expertise that is appropriate for the complexity of the
information being explained.
Clinically Significant Results: It is recommended that any clinically-significant laboratory results
ascertained through a research laboratory and disclosed to the research participant be validated
in an accredited clinical diagnostic laboratory to ensure that appropriate quality assurance measures
have been followed. Accredited clinical diagnostic laboratories that offer confirmation of research
findings can be identified using online databases such as GeneTests.org.
Unexpected Results: Genetic research is unique in that there is the potential to obtain information
about individuals or families that was unanticipated. In addition, it is possible that in the course of
studying one disease, a researcher may discover that an individual, family or community is at increased
risk for another, possibly unrelated, disorder. If individual results are to be disclosed, research participants
should be made aware of the possibility that unexpected results could be obtained and should
be informed of policy with regards to disclosure of such results in the context of significant
health implications for the individual and/or his family. Prior consent should be obtained with
regard to the research participant’s wish to be informed of these unanticipated results
Wolf SM, Lawrenz FP, Nelson CA, et al. Managing
Incidental Findings in Human Subjects Research:
Analysis and Recommendations (2008) [11].
Researcher should disclose IFs likely to offer strong net benefit from participant’s perspective: (a)
genetic information revealing significant risk of a condition likely to be life-threatening; (b) genetic
information that can be used to avoid or ameliorate a condition likely to be grave; and (c) genetic
information that can be used in reproductive decision-making: (1) to avoid significant risk for offspring
of a condition likely to be life-threatening or grave or (2) to ameliorate a condition likely to be
life-threatening or grave.
Researcher may disclose IFs offering possible net benefit from participant’s perspective: (a) genetic
information revealing significant risk of a condition likely to be grave or serious, when that risk
cannot be modified but a research participant is likely to deem that information important; and
(b) genetic information that is likely to be deemed important by a research participant and can
be used in reproductive decision-making: (1) to avoid significant risk for offspring of a condition
likely to be serious or (2) to ameliorate a condition likely to be serious.
Researcher should not disclose IFs offering unlikely net benefit from the participant’s perspective,
including information whose likely health or reproductive importance cannot be ascertained.
Zawati HZ et al. Reporting Results from
Whole-genome and Whole-exome Sequencing
in Clinical Practice: a Proposal for Canada?
[12] (endorsed by the Canadian College of
Medical Geneticists)
Prior to using [Whole Genome or Whole Exome Sequencing], physicians need to explain to their
patients the nature of the results that could arise, so as to allow them to make informed choices
over whether to take the test and which results they wish to receive.
Results revealing a clinically significant condition that is actionable during childhood should be
reported to the parents. Parents cannot refuse to receive such results.
The child’s views should be solicited and given due weight and consideration in accordance with
his or her age and maturity.
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protect participant privacy and prevent unauthorized
access to participant health information. The risk of
unauthorized identification of participants is an import-
ant characteristic of data intensive health research pro-
jects. It influences the extent of ethics review and
oversight that is required, if any. In some countries it
may also determine how privacy laws apply to the stor-
age, use, and dissemination of research samples and
data. Privacy laws generally apply to “identifying infor-
mation” and “identifiable individuals” [16]. A common
approach in research is to distinguish between direct
identifiers (name, health card number, telephone number
etc.) that alone or in combination “obviously” identify an
individual; and quasi-identifiers (postal code, date of birth
etc.) that may allow indirect re-identification. The danger
is that a third party outside the therapeutic or health re-
search relationship, such as an employer or insurer, links
sensitive health information (such as a genetic predispos-
ition to a disease) to a specific individual. This risk, how-
ever, is not altogether easy to define or mitigate. Health
research generally relies on two privacy protection mecha-
nisms: anonymization or coding [17]. Although inconsist-
encies remain in the terminology used by stakeholders,
anonymization is generally defined as the irreversible
removal of personal identifiers and quasi-identifiers
from sensitive health data. This mechanism is becoming
increasingly unpopular, especially in genetics research,
as it greatly reduces the scientific value of the samples
over time [17]. A more promising alternative is coding:
replacing identifiers with a unique, random code. The
identifiers are stored in a separate database along with
the code so that the process can be reversed. Security
can be further intensified with “double coding”, where
“the codes associated with the original data and the
identifier data set are different, and the information
linking them is kept in a separate linking database” [16].
This linking database is administered by an independent
third party intermediary, or “keyholder”. This double
coding structure is explained in more detail in the fol-
lowing section.
Where data is coded, researchers must link individual
health data back to personal identifiers in order to contact
the participant. Indeed, in studies involving the irrevocable
stripping of personal identifiers (“anonymization”), the
return of IRRs or IFs is rendered virtually impossible
[6,18]. In summary, research projects contemplating
feedback of IRRs or IFs will have to consider procedures
for both re-identification and communication.
The Liver Disease Project
The proposed framework addressing assessment, re-
identification, and communication was inspired by our
efforts to develop a feedback policy for the LiverDisease Project (LDP) located at Research Institute of
the McGill University Health Centre in Montréal, Québec.
The LDP integrates clinical management of liver disease
with high-end research analysis to identify new bio-
markers for the diagnosis, staging, and eventual treatment
of liver disease. Its main focus is complex polygenic and
chronic liver disease, namely Non-Alcoholic Fatty Liver
Disease (NAFLD), and its progression to Non-Alcoholic
Steatohepatitis (NASH), which puts patients at risk of
developing terminal liver disease. NAFLD comprises a
spectrum of liver conditions associated with the accumu-
lation of triglycerides in liver hepatocytes in the form of
lipid droplets, inflammation and fibrosis. The LDP em-
braces a “personalized” or “precision” medicine approach,
generating vast amounts of clinical data on patients to
identify biomarkers related to disease progression and re-
sponse to treatment. (See Figure 1) Knowledge of these
biomarkers could lead to improvement in individual prog-
noses and development of targeted treatments [19]. As
discussed above, this patient-centric research context
heightens the intensity of the researchers’ duty to feedback
individual research data. In other areas of research, such
as population biobanking, this feedback may be much
more difficult to implement [5]. Our framework is most
suitable for personalized medicine research projects in
Canada. It may provide a useful example to researchers in
other jurisdictions and research contexts contemplating
the feedback of individual research data.
The liver samples used for analysis by LDP researchers,
along with detailed, associated clinical information, are
stored in a Liver Disease Biobank (“Biobank”). Funded by
the Fonds de recherche du Québec – Santé, the Biobank is
a collection of high quality liver specimens taken mostly
from patients during surgical intervention, where tissue is
removed as part of treatment. To protect these sensitive
health data and samples, the Biobank relies on a double
coding system. Double coding is the separation of per-
sonal identifiers and samples (along with associated
clinical or research data) into two separate databases.
For each patient, one numerical code is assigned to the
personally identifying information, and a second, dis-
tinct code is assigned to the samples and data. These
two databases are mediated by a third “linkage” database
that contains a list pairing the two numerical codes for
each patient. Access to this third database is necessary
for re-identification of patients. For added security, the
linkage database is separately maintained, and accessible
only by an independent physician (the “keyholder”). In
short, the LDP is part of a double coded “biobank re-
search system” [6], comprising surgical collection of
samples, storage in the Liver Disease Biobank, and ac-
cess by LDP researchers for analysis. As we discuss
below, double coding protections present difficulties for
the handling and communication of IRRs and IFs.
Figure 1 The precision medicine approach of the Liver Disease Project. Legend: (None). *This is an original figure.
Thorogood et al. BMC Medical Ethics 2014, 15:88 Page 8 of 13
http://www.biomedcentral.com/1472-6939/15/88The LDP applies general assessment criteria to identify
IRRs and IFs. These general criteria are recommended
by several policy guidelines (See Table 1):
– Did the participant consent to return?
– Is the finding analytically valid? Analytical validity
considers the capacity of a test to measure the
characteristic it is designed to identify. In particular, is
the test precise, reliable, accurate, positive if the
genetic characteristic is present (analytical sensitivity),
and negative if it is absent (analytical specificity)?
– Is the finding clinically valid? Clinical validity is a
measure of the accuracy with which a test identifies
or predicts a clinical condition. It is defined in terms
of diagnostic specificity and sensitivity, positive
predictive value, and negative predictive value.
– Is the finding clinically useful, i.e. actionable?
Clinical utility considers the value of the results in
guiding the patient’s choices regarding prevention or
therapeutic strategies. The assessment of the utility
requires consideration of both the benefits and the
potential risks associated with the knowledge of the
result or indicated intervention.
In the Biobank consent form, participants were asked
to express their preferences regarding feedback of indi-
vidual health data:“If research using your samples reveals information we
were not looking for (i.e. incidental findings) and which
clearly indicate a significant health problem that can be
treated or prevented, then you will be informed by pro-
viding us a name of a physician who will transmit the in-
formation to you.”
“I would like to be informed, through my physician,
about incidental findings that indicate a significant health
problem. (YES/NO)”
Note that participants are given the option of designating
a physician to mediate the return of any significant health
information. Now that we have presented the context, and
the types of information we want to return to participants,
we turn to a discussion of the difficulties encountered in
the handling and communication of individual research
data to participants.
Discussion
A host of procedural issues hinder feedback of individual
research data [20]. Both assessment and communication
of IRRs and IFs require re-identification – breaking of
the double coding system – which generates privacy
risks. A feedback policy must carefully specify when, and
in what circumstances, a participant should be re-
identified. The roles of the Research Ethics Board, the
linkage database keyholder and the “designated physician”
(the clinician designated by the participant in the consent
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health information) remain unclear. We outline these
roles, and recommend that hospitals establish a formal,
interdisciplinary advisory committee to help researchers
review uncertain findings. Feedback policies must also
contemplate cases where participants refuse to be con-
tacted, and provide mechanisms to keep participant
contact information and feedback preferences up to
date.
Re-identification
Three procedural steps are required to return individual
research data: researchers must assess the analytical val-
idity, clinical validity (together “scientific validity”) and
clinical utility of an IRR or IF; the affected participant
must be re-identified; and the participant (or a desig-
nated physician) must be contacted [6]. Researchers
who commit to return IRRs of IFs must ensure adequate
resources and expertise are available to carry out these
steps. Determining the order of the steps, however, is
deceptively straightforward. Because breaking the code
creates privacy risks, it has been assumed that scientific
validities and clinical utility should be confirmed before
re-identification. We argue that in some cases it is prefera-
ble to re-identify the participant before such confirmations.
Confirming scientific validity involves expensive tests
and expert assessments. If participants can opt to refuse
re-contact about IRRs or IFs (as is the case with the
LDP), this preference should be established before con-
firming scientific validity. It is wasteful to confirm valid-
ity only to discover upon re-identification and inspection
of the consent form that the participant has refused re-
contact. Québec’s Network of Applied Genetic Medicine
(one of the few organizations offering procedural guid-
ance on the return of IRRs and IFs) recognizes this
problem, and suggests that scientific validity be estab-
lished after re-identification: “[i]n order to minimize the
operational impact of this condition on clinical labora-
tories, confirmation of the [genetic] results should only
be performed when the result satisfies [the other condi-
tions]” [7] (See Table 1).
Re-identification may also be necessary to fully assess
clinical utility. Unlike scientific validity, clinical utility
may require consideration of personal characteristics.
Assessing clinical utility involves weighing the benefits
and risks of disclosing individual health information.
Disclosure, however, will have little utility if the health
risk has already materialized, or if the participant has
passed away. Beyond these obvious examples, many
guidelines employ a broad definition of utility including
subjective factors such as participants’ reproductive in-
terests, or whether the information has implications for
their family members [6,12,21]. The definition may also
include personal utility for life planning, encompassingreturn of information on predispositions to untreatable
late-onset conditions. A biobank’s feedback policy should
clearly indicate how clinical utility will be assessed, and
whether or not re-identification should precede such as-
sessment. It should always be kept in mind that re-
identification carries risks to privacy and confidentiality
of data. Linkage should not be carried out without a
good reason.
Assessing whether to return a finding before re-
identification may be even more problematic if a popular
“binning” approach is used for the return of IFs. Binning is
the grouping of IFs into broad categories, usually along
the lines of scientific validity and clinical utility. Each
category can receive a different treatment by researchers,
such as “must return”, “may return”, “do not return.” For
“may return” findings, participants are asked whether or
not they want to receive the information. This process al-
lows participants to express their informational preferences
in a streamlined fashion [22]. Offering a comprehensive set
of options for the return or refusal of information, how-
ever, may increase the need to re-identify before confirm-
ing other conditions.
With foresight, researchers can address these conun-
drums. For example, participant preferences about re-
contact could be stored along with their research data and
sample, or even integrated into the numerical codes during
de-linkage. For example, a 0 added to the end of a partici-
pant code could signify a refusal to be re-contacted. Add-
ing a 1 could signify a preference for return. This way,
re-identification would not be required in order to assess
the consent criterion. Consideration of personal character-
istics may also be precluded before re-identification, or
even before re-contact. To address this problem, assess-
ment criteria must be carefully selected and ordered to
balance the privacy risk of re-identification against the
cost of assessment. For example, it may not be worth-
while to require researchers relying on a coded biobank
to consider subjective factors in the analysis of clinical
utility, (e.g. impact on reproductive decision making), if
such factors will remain unknown before re-identification.
Alternatively, objective aspects of clinical utility could be
considered before re-identification, and subjective aspects
could be considered afterwards.
The role of the Research Ethics Board
What role should the Research Ethics Board (REB) play
in handling IRRs and IFs? We argue that the REB should
not develop the feedback plan or assess whether or not an
IRR or IF should be returned. It should be researchers
who develop the plan, assess and confirm findings, and
communicate with participants and their designated phys-
ician. If the researchers analyzing the data have limited
expertise, or are analyzing limited data sets, this should be
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consent form. The primary role of the REB should be
to prospectively review the researcher’s feedback pol-
icy. The researcher would be responsible for imple-
mentation. Such an approach is endorsed by Québec’s
Network of Applied Genetic Medicine’s 2013 Statement of
Principles on the Return of Research Results and Incidental
Findings.
Apart from the Statement, there is little explicit descrip-
tion of the REB’s role in the handling of IRRs and IFs in
other guidelines. Canada’s Tri-Council Policy Statement:
Ethical Conduct for Research Involving Humans (2010)
(“TCPS2”) does not currently describe procedures for
handling IRRs and IFs, except to say that researchers
should “develop a plan” of how they will communicate to
participants and submit to the REB (art 3.4). This rule ap-
plies to all genetic researchers (art 13.2(a)) and other re-
searchers where material IFs are likely. The steward of the
policy, the Interagency Advisory Panel on Research Ethics,
is proposing to amend the TCPS2 to provide an expanded
role for REBs in handling procedures. The proposed text
would read: if material IFs are discovered, “researchers
shall report them to the REB … The researcher should
provide enough information to enable the REB to de-
termine whether the [IFs] are material, and to assess
the risks and benefits of disclosing the findings to the
participant” [23]. If these proposed changes are ac-
cepted, REBs would become responsible for confirm-
ation of IRRs and IFs.
REBs should not have the responsibility to assess the
risks and benefits of returning individual IRRs or IFs en-
countered in research. They are unlikely to have the
clinical and scientific expertise to make this type of as-
sessment for research projects. Assessments also require
significant time, expense, and resources already in short
supply for REBs. Researchers, on the other hand, areFigure 2 Outline of a feedback procedure for IRRs and IFs. Legend
individual research data, and the roles of the Research Ethics Board (R
original figure.more likely to have the expertise and familiarity with
their own scientific methods to assess IRRs and (albeit
to a lesser extent) IFs, or to know clinicians that do. If
researchers feel compelled to deviate from a previously
approved return plan, or are uncertain about a particular
complex finding, they can consult their clinical col-
leagues or their REB on a case-by-case basis. Ideally, a
formal, clinical advisory committee would be established
and maintained in research hospitals. It would convene
on an ad-hoc basis at the request of principal investigators
to evaluate findings. Given the issues involved in deciding
to return IRRs or IFs, this committee would include physi-
cians, geneticists, ethicists, and lawyers. Our recommen-
dation is supported by recently published U.S. guidelines:
“Researchers who discover an unanticipatable incidental
finding of concern should assess its significance, consult-
ing with experts as appropriate” [24]. This flexible ap-
proach allows for the rapid return of clear and serious
health risk information, while providing for deliber-
ation in less certain cases. Once a decision is taken to
return findings, the principal investigator should com-
municate directly with the participant or designated
physician. Principal investigators should not seek approval
from the REB before communication; rather, they should
notify the REB of the decision and the means of com-
munication. The complete return procedure we propose
is illustrated in Figure 2.Keyholder guidelines
In a biobank with a double coding system, the linkage
database that contains the numerical codes linking samples
and data to personal identifiers is held by a trusted inter-
mediary or “keyholder.” A researcher wishing to feedback
individual research data must first re-identify the affected
participant. Re-identification implicates the keyholder: This image details the steps in a procedure for the feedback of
EB), Keyholder, and Principle Investigator (PI). *This is an
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the keyholder’s role here:
1. The linkage database must be kept separate from the
databases holding personal identifiers and sensitive
health information.
2. To the extent possible, the keyholder should be
independent from the research project.
3. The keyholder should be a physician informed of the
criteria for return and able to assess them. To
adequately safeguard participant privacy, the
keyholder should be instructed of all situations
where re-identification is necessary, and the conditions
related to each.
4. The keyholder is authorized to re-identify participants
in certain circumstances, which should be clearly
delimited at the start of the project.
5. Before re-identification for the purpose of feeding back
IRRs or IFs to individual participants, the keyholder
must receive a request in writing from the biobank
director. This written request will confirm that the
participant has consented to return, and that the
return criteria (analytical/clinical validity etc.) have
been met.
6. The keyholder will take all reasonable measures
to ensure the participant’s privacy before and
after linkage.
7. The keyholder will keep a written record of all
re-identifications and requests for re-identification.
The role and responsibilities of the keyholder must be
clearly articulated at the start of a research project to ensure
that the double coding system does not prevent return of
important health information to participants, or unneces-
sarily put their privacy at risk.
Additional procedural issues
Replacing personal identifiers with a code, or a double
code, reduces the number of identity cross-checks and
increases the chance of an error in sample labelling and
tracking [3]. Biobanks planning to provide personal feed-
back will want to ensure the utmost care in sample
tracking and labelling. Return of erroneous risk informa-
tion to participants may lead to unnecessary anxiety and
follow-up, and may even expose researchers to legal li-
ability if harm results.
Researchers may offer participants the option to refuse
re-contact about health information. This respects their
right not to know, their right to “decide whether or not
to be informed of the results of genetic information and
the resulting consequences…” [25]. An individual’s inter-
est in not knowing may be heightened in the research
context, as they have not expressly sought out diagnosis.
Some suggest that the option to refuse re-contact insome research contexts should extend even to treatable,
clinically significant findings [26]. The fidelity of such re-
fusals, however, may be suspect, especially if a serious risk
is encountered years later, or if the participant’s opinion or
attitude towards research changes. In biobanking projects,
researchers may have little or no contact with participants
after the original consent. It is difficult to know if partici-
pants’ wishes expressed in the original consent form con-
tinue to reflect their true wishes. Refusal to be re-contacted
tends to be given broadly: individuals refuse to be re-
contacted about a general category (or categories) of find-
ings. Researchers may therefore suspect that participants
opting-out of return of individual research data did not
fully understand what they were refusing. In addition, re-
searchers confronted by serious, valid, and actionable IRRs
or IFs may feel that their professional duty to warn (or
rescue) the participant (and the correlative risk of legal li-
ability for failure to do so) may over-ride the participant’s
refusal to be informed [13]. As a compromise, some au-
thors have suggested that researchers should “reconfirm
with a research participant who indicated refusal that he
or she is electing to decline information” on all IRRs or
IFs [11]. The opposite problem could also occur: a re-
searcher may attempt to return a result to a participant
who opted for re-contact, only to find that the partici-
pant is no longer interested. The Network of Applied
Genetic Medicine recognizes this latter situation, and
recommends that researchers “confirm the desire to re-
ceive results before returning them” [7]. But how can
this desire be ascertained? Perhaps the initial communi-
cation to the participant can be broad and impersonal
in order to conceal risk information (as much as prac-
tically possible) until their preferences are established.
But this could delay treatment or cause participants to
misapprehend the nature of the risk researchers hope to
communicate. Alternatively, direct communication to
participants may undermine their control over the flow
of information. This is a classic difficulty with respect-
ing the right not to know: it may be impossible to divine
the participant’s preference without revealing something
about the nature of the risk information.
Participant contact information and re-contact prefer-
ences should be updated where possible, and procedures
should be in place to address situations where the affected
participant is not readily contactable. Our Feedback Policy
for the LDP requires the principal investigator to take rea-
sonable but limited steps to locate a participant, such as
asking the participant’s treating physician, asking known
relatives, or carrying out a basic internet search. The final
communication also poses procedural challenges and
requires design choices. Some researchers suggest that
disclosure be made “directly to the research participant”
[11]. Others prefer disclosure to the research partici-
pant’s primary care physician [27]. Disclosure directly to
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control over his or her health information and privacy
[11]. The participant should be able to decide who to
consult and what is entered into his or her medical re-
cords. Another solution, adopted by our project, is to
ask the participant to designate a physician on the con-
sent form to mediate the return of significant individual
health information. Feedback policies should also be
careful to clearly limit the scope of the duties of re-
searchers (including temporal limitations). For Wolf
and colleagues [6], “the goal [of return is] not to supply
clinical care or a clinical work-up of the finding, but to
put the participant in the position to make an informed
decision about what next steps to take, including seek-
ing clinical work-up and care.” Finally, both the partici-
pant and/or the designated physician may need to be
informed of the possibility of false positives due to an
inaccurate test result (in the case of an IF) or a coding
error during re-identification. Where feasible, follow-up
testing should be recommended.
Summary
The return of IRRs and IFs is an essential frontier for
the translation of research findings into clinical solu-
tions. Clear, efficient and ethical processes are needed to
guide the handling of IRRs and IFs, and ultimately to
improve patient care. Our central recommendations are
summarized here:
 Researchers planning to return IRRs and IFs should
prospectively develop a clear procedure for the review
and communication of findings. This procedure
should take into account the privacy protections in
place and clearly articulate the role of researchers, the
REB, and the keyholder in the return process.
 The primary role of the REB is to prospectively
review the researcher’s return policy and
procedures. The REB should not generally be
directly involved in the review of candidate IRRs
and IFs, but should be notified of the advisory
committee’s recommendation and the principal
investigator’s decision on whether or not to
communicate findings.
 A formal, interdisciplinary clinical advisory
committee should be established, preferably by
research institutions, to convene on an ad-hoc
basis and advise researchers on the handling of
uncertain findings.
 If a double coding system is employed, the role of
the keyholder in the return process needs to be
clearly articulated. The keyholder should be
informed of the situations where IRRs and IFs will
be returned, and the conditions that must be met to
justify re-identification. Researchers should facilitate the update of
participant contact information and provide
participants with the opportunity to express clear
preferences about re-contact.
Coding protection systems are important means of
privacy protection, but present a hurdle to the feedback
of individual research data to participants. Researchers
can avoid some issues by upstream design. Projects
should outline clear procedures for the assessment of
individual research data, re-identification of participants,
and communication to participants and designated physi-
cians. The role of the REB in the handling of IRRs and IFs
should generally be limited to review of the researcher’s
feedback policy. The REB may, however, act as an advisor
when researchers are uncertain of how to proceed, espe-
cially if an advisory committee has not been established.
REBs should also be notified of the principal investigator’s
feedback decisions. Researchers relying on biobanks using
double coded systems will also need to provide clear guid-
ance for the keyholder responsible for the linkage data-
base. Finally, researchers and their funders must take into
account the considerable costs and infrastructure required
for the design and implementation of a feedback policy.
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